Drug Resistance in Pneumonia (DRIP) Score
ورودیهای بالینی بیمار
پارامترهای بالینی بیمار را در فرم روبرو وارد کنید و روی «محاسبه» کلیک نمایید تا نمره، طبقه خطر و اقدامات فوری نمایش داده شوند.
- Low Risk0–3
- High Risk4–14
The Drug Resistance in Pneumonia (DRIP) Score calculates predicting risk for community-acquired pneumonia due to drug-resistant pathogens (CAP-DRP). Key inputs include antibiotic use 60 days. Scores guide administering empiric broad-spectrum antimicrobial regimens, infectious source control, and isolation protocols. This standardized assessment improves clinical decision safety and bedside patient management.
Clinical Guidelines & Evidence
Predicts risk for community-acquired pneumonia due to drug-resistant pathogens (CAP-DRP). Helps determine when broad-spectrum antibiotics should be used to ensure effective treatment while avoiding unnecessary antibiotic resistance.
Clinical Indication
The Drug Resistance in Pneumonia (DRIP) Score is indicated for bedside clinical practice to support Predicts risk for community-acquired pneumonia due to drug-resistant pathogens (CAP-DRP). Helps determine when broad-spectrum antibiotics should be used to ensure effective treatment while avoiding unnecessary antibiotic resistance.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.
Target Population
Target population comprises Patients presenting with suspected sepsis, meningitis, pneumonia, COVID-19, opportunistic infections, or fever of unknown origin. Clinical application is indicated across Infectious disease services, septic shock bays, febrile illness clinics, and isolation units.
Limitations & Contraindications
Timely administration of empiric antibiotic therapy in suspected septic shock must never be delayed for score tabulation.
Clinical Pearls & Action Plan
Blood and site-specific microbiological cultures should be secured prior to administering broad-spectrum antimicrobials. Guideline pearl: At threshold ≥4 points: Sensitivity 0.82, Specificity 0.81, PPV 0.68, NPV 0.90..
Major risk factors (2 points each): Antibiotic use within 60 days, Long-term care facility residence, Tube feeding, Prior drug-resistant infection. Minor risk factors (1 point each): Chronic pulmonary disease, Hospitalization within 60 days, Poor functional status, MRSA colonization, Wound care, Gastric acid suppression. Total: 0-14 points.
Input Parameters
| Name | Type | Required | Description |
|---|---|---|---|
| antibiotic_use_60_days | string | Yes | Antibiotic use within 60 days (Major risk factor) |
| long_term_care_facility | string | Yes | Residence in a long-term-care facility (Major risk factor) |
| tube_feeding | string | Yes | Tube feeding (Major risk factor) |
| prior_drug_resistant_infection | string | Yes | Prior infection with a drug-resistant pathogen (Major risk factor) |
| chronic_pulmonary_disease | string | Yes | Chronic pulmonary disease (Minor risk factor) |
| hospitalization_60_days | string | Yes | Prior hospitalization within 60 days (Minor risk factor) |
| poor_functional_status | string | Yes | Poor functional status (Minor risk factor) |
| mrsa_colonization | string | Yes | MRSA colonization (Minor risk factor) |
| wound_care | string | Yes | Wound care (Minor risk factor) |
| gastric_acid_suppression | string | Yes | Gastric acid suppression (Minor risk factor) |
Score Interpretation & Guidance
| Range | Stage | Description |
|---|---|---|
| 0–3 | Low Risk | Low risk of drug-resistant pneumonia |
| 4–14 | High Risk | High risk of drug-resistant pneumonia |
Evidence-Based References (EBM)
- Webb BJ, Dascomb K, Stenehjem E, Dean N. Derivation and multicenter validation of the drug resistance in pneumonia clinical prediction score. Antimicrob Agents Chemother. 2016;60(5):2652-63. doi: 10.1128/AAC.03071-15.DOI: 10.1128/AAC.03071-15
- Attridge RT, Frei CR, Restrepo MI, et al. Guideline-concordant therapy and outcomes in healthcare-associated pneumonia. Eur Respir J. 2011;38(4):878-87. doi: 10.1183/09031936.00141110.DOI: 10.1183/09031936.00141110
- Webb BJ, Dangerfield B, Pasha JS, et al. Guideline-concordant antibiotic therapy and clinical outcomes in healthcare-associated pneumonia. Respir Med. 2012;106(11):1606-12. doi: 10.1016/j.rmed.2012.08.010.DOI: 10.1016/j.rmed.2012.08.010